Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
No open-market purchase by an insider of Viatris was filed in the last 90 days. The latest on record was on Mar 10, 2026.
How often do Viatris insiders buy and sell shares?
Since 2020, Viatris insiders reported 10 open-market purchases and 32 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2025.
Who is selling Viatris stock?
No open-market sale by an insider of Viatris (VTRS) was filed with the SEC in the last 90 days.
Do members of Congress trade VTRS?
Yes. Members of Congress disclosed 1 trade in Viatris (VTRS) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Gilbert Ray Cisneros Jr. (CA31).
When does Viatris report its next results?
Viatris's next results are expected on Feb 24, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$20.28−0.17 (−0.83%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+89.4% (+$9.57) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $10.71 on Nov 18, 2025 to $20.28 on Nov 18, 2026 (+89.4%). Disclosed in this range: 1 insider trade, 1 pre-arranged insider sale, 1 Congress trade, and 24 13F position changes for 4 quarters ending in it.
$5$10$15$25$20.28
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 3 trades in this range as a list
Paul Campbell, See Remarks · Pre-arranged insider sale, about $810Ktraded Jun 25, 2026, filed Jun 26, 2026
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceuticals company based in Pittsburgh, Pennsylvania.
Last 12 months
+89.4%
S&P 500 +10.6% over the same dates
Market value
$23.3B
Close of Nov 18, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 35.2M shares sold short (3.1% of shares outstanding), −7.1% vs the previous count, 4.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
$3.75B
−0.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$2.11B
This quarter $814M, a year earlier $658M
Net debt
$11.5B
Debt $13.3B, cash $1.79B, at Sep 30, 2026
Net income, last 12 months
—
Operating profit covers interest 0x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
33 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
33 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
33 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Viatris reported 10 open-market purchases and 32 sales since 2020; purchases in 4 different years, most recently 2025.
Year
Bought
Sold
2026
—
$1.09M2×2 trades
2025
$761K4×4 trades
$72K1×1 trade
2024
—
$15.9M19×19 trades
2023
—
$310K5×5 trades
2022
$524K2×2 trades
$5.43M5×5 trades
2021
$73K3×3 trades
—
2020
$490K1×1 trade
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Late-stage clinical trials
5 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in lupus erythematosus, systemic, acute myocardial infarction, sle - systemic lupus erythematosus. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
When insiders usually buy
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 24, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
73%
11 of 15 insider purchases since 2020 came within 30 days after a results announcement
From Viatris's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Viatris's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Risk factors in the annual report
Latest annual report filed Feb 26, 2026, compared with the one filed Feb 27, 2025. Read the filing
New risk factors in the latest annual report (3 headings)
Viatris’ restructuring activities may not achieve their intended goals and may present significant challenges, which could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, and/or stock price.
The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business, as well as any retaliatory actions with respect to such actions, could have a material adverse effect on our business, financial condition, results of operations, cash flows, ability to pay dividends or repurchase shares, and/or stock price.
Incorporating ML, AI and other emerging technologies into our products, services and operations may result in legal and regulatory risks, reputational harm or have other adverse consequences to our business, financial condition or results of operations.
Legal proceedings (Item 3)
For information regarding legal proceedings, refer to Note 20 Litigation included in Part II, Item 8 of this 10-K.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Short sale volume: 50.5% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 47.4%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 132K shares (about $2.47M) were not delivered on time for settlement on Oct 28, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 46.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (23.4% on ATS, 23.4% with other brokers), above its 26-week average of 43.1%. Weeks of Oct 5 to Oct 30, 2026.
May 14, 2026Busiest day: 550 views on Oct 8, 2026Nov 18, 2026
Views of the article Viatris, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: INTELLIGENT CROSS LLC (14.2%), BIDS ATS (10.1%), UBS ATS (9.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Viatris filed 2 open-market purchases (about $5.2K, in 1 filing, by 1 person) and 2 open-market sales (about $1.09M, in 2 filings, by 1 person). One Form 4 can list many transactions. In the 12 months before that, they filed 2 open-market purchases (about $756K, in 2 filings) and 1 open-market sale (about $72K, in 1 filing). (Viatris on OQRO)
Congress. Members of Congress filed 1 disclosure on Viatris in the 12 months to Nov 19, 2026: 1 purchase and 0 sales, by 1 member. In the 12 months before that: 3 disclosures. The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $1,001 to $15,000, filed Dec 15, 2025.
Funds and stakes. Fund 13F filings recorded in the 12 months show 15 new or larger positions and 10 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter. FMR LLC now owns 8.3% of VTRS as a passive investor (filed Aug 6, 2026).
Contracts, lobbying and filings. 9 lobbying reports naming the company were posted in the 12 months, reporting about $1.7M. The Federal Register published a notice, "Jeffrey Thies: Final Debarment Order", on Sep 25, 2026, naming the company.
Company reports, price and press. Viatris filed a Form 8-K on Nov 17, 2026 (Items 2.01, 7.01) that OQRO classes as: completed buying or selling a business or assets, and shared information with investors. The company's own opening sentence of that report reads: "As previously disclosed, on October 8, 2026, Viatris Inc., a Delaware corporation ('Viatris'), entered into an Agreement and Plan of Merger (the 'Merger Agreement') with Pacira BioSciences, Inc., a Delaware corporation ('Pacira')..."
Who holds it. 1,020 funds reported a stake in Viatris in their 13F for Q2 2026. The largest by value: FMR LLC (9.2% of the value reported), BlackRock, Inc. (8.2% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (7.2% of the value reported).
Deals. Viatris is the buyer of Pacira BioSciences, Inc.; status: completed, first on record Oct 8, 2026. Viatris is the target of Harrow, a deal of about $30M; status: completed, first on record Aug 6, 2026.
Attention. The English Wikipedia article on Viatris was read about 162 times a day in the 7 days to Nov 18, 2026, against a usual 162 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Viatris filed 2 open-market purchases (about $5.2K, in 1 filing, by 1 person) and 2 open-market sales (about $1.09M, in 2 filings, by 1 person). One Form 4 can list many transactions.
In the 12 months before that, they filed 2 open-market purchases (about $756K, in 2 filings) and 1 open-market sale (about $72K, in 1 filing).
The largest purchase: David S Simmons, Director, about $3K, filed Mar 10, 2026.
The largest sale: Paul Campbell, See Remarks, about $810K, filed Jun 26, 2026.
Congress
Members of Congress filed 1 disclosure on Viatris in the 12 months to Nov 19, 2026: 1 purchase and 0 sales, by 1 member. In the 12 months before that: 3 disclosures.
The largest range: Rep. Gilbert Ray Cisneros Jr. (CA31), $1,001 to $15,000, filed Dec 15, 2025.
Funds and stakes
Fund 13F filings recorded in the 12 months show 15 new or larger positions and 10 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
FMR LLC now owns 8.3% of VTRS as a passive investor (filed Aug 6, 2026).
Contracts, lobbying and filings
9 lobbying reports naming the company were posted in the 12 months, reporting about $1.7M.
The Federal Register published a notice, "Jeffrey Thies: Final Debarment Order", on Sep 25, 2026, naming the company.
FDA records list 7 recalls, 10 drug approvals for Viatris between Nov 19, 2025 and Nov 19, 2026; the latest, on Oct 1, 2026: recall for Telmisartan and Amlodipine, Tablets, USP, 40mg/5 mg, 30-count Bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA, Made in… (Superpotent Drug: potential for the Telmisartan content in these lots to exceed specifications).
ClinicalTrials.gov shows 7 studys sponsored by the company updated in the period; the latest, "A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of..." (Phase 2, status recruiting), was updated on Nov 6, 2026, with primary completion listed for 2027-11-30.
FINRA short interest for VTRS on the settlement date of Oct 30, 2026 was 35,240,834 shares (-7.08% on the previous report), about 4.04 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 453,568 shares); the largest that shrank: none on record. A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $15.3M for its principal executive officer, and an average of $5.15M for the other named executive officers.
Company reports, price and press
Viatris filed a Form 8-K on Nov 17, 2026 (Items 2.01, 7.01) that OQRO classes as: completed buying or selling a business or assets, and shared information with investors.
The company's own opening sentence of that report reads: "As previously disclosed, on October 8, 2026, Viatris Inc., a Delaware corporation ('Viatris'), entered into an Agreement and Plan of Merger (the 'Merger Agreement') with Pacira BioSciences, Inc., a Delaware corporation ('Pacira')..."
Viatris filed a Form 8-K on May 4, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
Viatris filed a Form 8-K on Feb 26, 2026 (Items 2.02, 2.05, 8.01) that OQRO classes as: announced job cuts, closures or a restructuring, and reported its results (and 1 more item).
The company's own opening sentence of that report reads: "On February 26, 2026, the Company announced the results of its EWSR, and as a part of the review, committed to and began implementation of certain restructuring activities."
VTRS closed at $20.28 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $18.26 to $20.28, a change of +11.1%.
Who holds it
1,020 funds reported a stake in Viatris in their 13F for Q2 2026. The largest by value: FMR LLC (9.2% of the value reported), BlackRock, Inc. (8.2% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (7.2% of the value reported).
Deals
Viatris is the buyer of Pacira BioSciences, Inc.; status: completed, first on record Oct 8, 2026.
Viatris is the target of Harrow, a deal of about $30M; status: completed, first on record Aug 6, 2026.
Attention
The English Wikipedia article on Viatris was read about 162 times a day in the 7 days to Nov 18, 2026, against a usual 162 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Since Nov 17, 2025, VTRS is up 90.2% and the index fund is up 9.7%: 81 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much VTRS moves
A usual day
±1.1%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
2.9%Average distance between the low and the high of a session, over the last 14.
Largest one-day fall
−7.7%Aug 6, 2026
Largest one-day rise
+9.0%May 7, 2026
Deepest fall of the year
−19.7%From the close of Feb 11, 2026 to Mar 30, 2026.
Days of 5% or more
7Out of 252 sessions, in either direction.
Beta 0.7(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).